Neurogene Inc

Healthcare · Biotechnology · —

25.50$ -3.9% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Balance Sheet

Neurogene Inc (NGNE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 244 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet NGNE
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	164	154	143	133	122	110	96	104	88	78	75	74	70	147	153	145	222	211	200	187	176	163	149	137	127	109	98	74	90	223	195	180	164	336	315	297	288	289	263	244
Current Assets	147	103	122	132	121	109	94	103	87	77	75	73	68	144	140	131	207	195	181	167	156	144	130	118	109	85	86	49	80	200	174	159	144	316	296	279	271	272	247	229
Cash	86	32	21	27	47	52	67	99	87	77	74	73	66	143	139	130	202	193	179	165	156	142	128	78	40	82	35	46	25	148	150	111	67	137	71	59	71	104	124	112
Cash & Short-Term Investments	146	103	122	131	120	108	93	102	87	77	74	73	66	143	139	130	202	193	179	165	156	142	128	116	107	82	83	79	79	197	170	154	139	312	293	275	265	269	243	225
Receivables	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.6	0.6	–	0.6	0.6	0.6	0.7	0.6	0.6	1.3	0.9	0.5	–	–
Inventory	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.0	2.0	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	–	–	–	–	–	–	–	–	–	–	–	0.6	0.6	0.5	0.5	0.4	0.3	0.3	0.2	0.2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	8.7	9.7	6.4	8.7	7.5	11	9.8	14	11	4.9	3.9	1.4	2.9	5.3	16	17	21	19	21	20	21	20	19	20	21	11	17	257	14	37	25	25	27	25	24	24	22	24	25	27
Current Liabilities	8.6	9.5	5.8	8.1	7.0	11	9.4	13	11	4.6	3.6	1.2	2.6	4.7	5.6	6.3	9.9	7.9	8.4	7.6	9.0	8.6	7.6	9.3	10	6.7	7.2	9.4	5.2	23	12	13	16	15	14	15	15	16	19	22
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	–	0.2	0.3	0.6	0.6	0.3	0.4	0.7	1.1	1.2	1.2	1.2	1.3	1.4	1.4	0.7	1.7	1.6	2.3	2.9	2.7	2.8	3.7	3.0	4.2	4.3	3.7	3.1	3.0	3.0
Accounts Payable	–	–	–	–	–	–	–	13	11	4.6	3.4	1.0	2.3	1.6	–	–	–	1.3	–	–	–	0.5	–	–	9.5	0.6	1.5	2.1	2.1	2.6	1.5	1.7	1.7	1.3	3.1	2.1	1.5	2.0	4.7	3.3
Shareholders' Equity	155	145	137	125	114	99	86	91	77	73	72	72	67	142	137	129	200	191	179	167	155	143	130	117	106	99	81	-183	75	186	171	155	137	310	292	273	266	265	238	217
Retained Earnings	-137	-148	-157	-170	-182	-199	-213	-210	-225	-230	-232	-232	-291	-300	-308	-318	-320	-333	-348	-363	-378	-393	-409	-425	-438	-151	-465	-190	-472	-187	-204	-223	-243	-262	-285	-307	-328	-353	-384	-418
Shares Outstanding	18	23	23	23	23	23	23	24	24	24	24	24	26	35	49	49	54	42	55	55	55	42	55	55	43	43	55	128	11	13	17	17	17	15	21	21	21	15	22	23

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings